PLK1 and posterior cortical atrophy: These findings in the xenograft mouse model render the potential to improve treatment efficacy for PCa patients with this combinational strategy because mono treatment with 5‐Aza upregulates Plk1 expression which provides targets for Plk1 inhibitors.